Happy People, Happy Hearts? Ultra-Processed Foods and Diabetes Risk Also in TTHealthWatch: AACR report on cancer Sep 28, 2024 podcast
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says Despite problematic dataset, risk/benefit profile not favorable with PD-L1 expression below 1 Sep 27, 2024
Certain Oral Bacteria May Be a Risk Factor for Head and Neck Cancer An increase in microbial risk score based on 22 bacteria tied to a 50% increase in HNSCC risk Sep 27, 2024
Insurance Claim Denials for Preventive Care More Common in At-Risk Patients Study suggests differences in how the ACA cost-sharing exemption is applied across patient groups Sep 27, 2024 video
Timely Skin Cancer Screening After Organ Transplant Still Lacking Only a minority of patients adhered to SUNTRAC screening recommendations Sep 26, 2024
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement News, features, and commentary about cancer-related issues Sep 26, 2024
GOP Doctor Vying for House Seat in Kansas Air Force, Harvard Business School, clinical practice all part of Prasanth Reddy's resume Sep 26, 2024
Sickle Cell Disease Drug Pulled From Global Markets Benefits of voxelotor (Oxbryta) no longer outweigh the risks, Pfizer says Sep 26, 2024
FDA Expands Approval of Osimertinib in Lung Cancer EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy Sep 25, 2024
Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic Actual rates for 2021 lagged behind projections Sep 25, 2024
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis Fidanacogene elaparvovec reduces bleeding episodes by 71% after a single infusion Sep 25, 2024
Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer Strategy comes with associated "low risk" of delay in diagnosis of advanced or incurable cancers Sep 25, 2024
'Sex Party' COVID Czar Fired; Undiagnosed Iron Deficiency; Many Papers Partly Fake? Health news and commentary gathered by 番茄社区app staff Sep 25, 2024
ASCO's Quality Care Symposium: Chemotherapy Shortage Resulted in Higher Costs Other studies look at financial toxicity for teen/young adult cancer patients, nausea after chemo Sep 24, 2024
Immunotherapy May Not Benefit All Gastroesophageal Cancer Patients, FDA Staff Says Data since approvals suggest benefits limited to subgroups with PD-L1 expression of at least 1% Sep 24, 2024
EPA Scientists Say They Were Pressured to Downplay Health Harms From Chemicals And a watchdog found they were retaliated against Sep 22, 2024
High ADHD Medication Doses Tied to Psychosis; Rapid Tests for Malaria Also in TTHealthWatch: youth and opioids, and pembrolizumab for triple-negative breast cancer Sep 21, 2024 podcast
Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms? News, features, and commentary about cancer-related issues Sep 19, 2024
Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian Cancer Poorer survival outcomes plus more toxicity versus rucaparib alone Sep 18, 2024
Novel Agent Effective for Cancer Wasting Disorder Cancer patients with cachexia added needed pounds with GDF-15 antibody Sep 18, 2024
Lymphedema Risk No Higher With 3-Week RT Regimen in Early Breast Cancer "Nodal radiotherapy for breast cancer no longer needs 5 weeks," researcher says Sep 17, 2024
FDA Expands Approval of Ribociclib to Early Breast Cancer Broad indication doubles the number of patients eligible for adjuvant CDK4/6 inhibition Sep 17, 2024
Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer Absolute difference of 4.9% at 5 years, including a benefit for patients who did not achieve pCR Sep 17, 2024
Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors Potential new option for patients with previously treated extrapancreatic or pancreatic NETs Sep 17, 2024
Digital Breast Tomosynthesis May Reduce Development of Advanced Cancers Retrospective study suggests benefits over digital mammography Sep 17, 2024
Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer Results "practice-changing," says expert Sep 16, 2024
Medical Cannabinoids in Kids Linked to These Adverse Events Meta-analysis points to considerations for use and what to monitor Sep 16, 2024
Another Possible Treatment Option for Intermediate-Stage Liver Cancer Adding lenvatinib, pembrolizumab to TACE significantly improved PFS, numerically improved OS Sep 16, 2024
Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation Regimen tops best historical response rate with chemoimmunotherapy in this setting Sep 16, 2024
Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival Hazards for radiographic PFS, OS reduced by 31% with enzalutamide plus Ra-223 Sep 15, 2024
Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer POD1UM-303/InterAACT 2 data also trend in the direction of better overall survival Sep 15, 2024
No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer But combination may be appropriate for shrinking tumors before surgery Sep 14, 2024
Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain Mets Second-line T-DXd best option in patients with and without intracranial activity, experts says Sep 14, 2024
Screening After False Positive Mammograms; RSV Vaccination and Hospitalization Also in TTHealthWatch: time from approval to reimbursement for new drugs Sep 14, 2024 podcast
No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma Data support that ICI rechallenge should be discouraged in patients with advanced RCC Sep 13, 2024
Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer News, features, and commentary about cancer-related issues Sep 12, 2024
How a California Oncologist Making $850k Spends Money See the breakdown of this physician's weekly budget, from eating out to sailing lessons Sep 12, 2024
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments Incidence almost identical to that with standard cancer treatment in randomized trials Sep 11, 2024
Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan Sep 11, 2024
Limits to Anti-Nausea Pill Coverage Wear on Cancer Patients and Doctors "This is sort of the dirty underbelly of the current healthcare environment," an oncologist said Sep 11, 2024
